|
2024 Journal Article Variation in immunoglobulin use and impact on survival in myelomaChai, Khai Li, Wellard, Cameron, Thao, LTP, Aoki, Naomi, Moore, Elizabeth M, Augustson, Bradley M, Bapat, Akshay, Blacklock, Hilary, Chng, Wee J, Cooke, Rachel, Forsyth, Cecily J, Goh, Yeow‐Tee, Hamad, Nada, Harrison, Simon J, Ho, P Joy, Hocking, Jay, Kerridge, Ian, Kim, Jin Seok, Kim, Kihyun, King, Tracy, McCaughan, Georgia J, Mollee, Peter, Morrissey, C Orla, Murphy, Nick, Quach, Hang, Tan, Xuan Ni, Tso, Allison CY, Wong, Kimberly SQ, Yoon, Sung‐Soo ... McQuilten, Zoe K (2024). Variation in immunoglobulin use and impact on survival in myeloma. eJHaem, 5 (4), 690-697. doi: 10.1002/jha2.938 |
|
2024 Journal Article Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapseHo, P. Joy, Spencer, Andrew, Mollee, Peter, Bryant, Christian E., Enjeti, Anoop K., Horvath, Noemi, Butcher, Belinda E., Trotman, Judith, Gibbs, Simon and Joshua, Douglas E. (2024). Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse. Clinical Lymphoma Myeloma and Leukemia, 24 (8), 543-552. doi: 10.1016/j.clml.2024.04.001 |
|
2024 Journal Article Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)Mollee, Peter, Reynolds, John, Janowski, Wojt, Quach, Hang, Campbell, Philip, Gibbs, Simon, Lee, Sophie, Lee, Edwin, Taylor, Kerry, Cochrane, Tara, Wallington-Gates, Craig, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian, Weston, Helen, Ho, P. Joy, Leahy, Michael F, Horvath, Noemi and Spencer, Andrew (2024). Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16). Blood Advances, 8 (14), 3721-3730. doi: 10.1182/bloodadvances.2023012539 |
|
2024 Journal Article The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)Ho, P. Joy, Moore, Elizabeth, Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrrison, Simon J., MacDonald, Emma‐Jane, McQuilten, Zoe K., Wood, Erica M., Mollee, Peter and Spencer, Andrew (2024). The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). British Journal of Haematology, 205 (4), 1337-1345. doi: 10.1111/bjh.19624 |
|
2024 Journal Article Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 studyNinkovic, Slavisa, Harrison, Simon J, Lee, Je-Jung, Murphy, Nick, Lee, Jae Hoon, Estell, Jane, Chen, Vivien M, Horvath, Noemi, Kim, Kihuyn, Eek, Richard, Augustson, Bradley, Bang, Soo-Mee, Huang, Shang-Yi, Rajagopal, Rajeev, Szabo, Ferenc, Engeler, Daniel, Butcher, Belinda E, Mollee, Peter, Durie, Brian, Chng, Wee Joo and Quach, Hang (2024). Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study. Haematologica, 109 (7), 2229-2238. doi: 10.3324/haematol.2023.284238 |
|
2024 Journal Article 2024 Australia–New Zealand Expert Consensus Statement on Cardiac AmyloidosisBart, Nicole K., Fatkin, Diane, Gunton, James, Hare, James L., Korczyk, Dariusz, Kwok, Fiona, Lam, Kaitlyn, Russell, David, Sidiqi, Hasib, Sutton, Tim, Gibbs, Simon D.J., Mollee, Peter and Thomas, Liza (2024). 2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis. Heart, Lung and Circulation, 33 (4), 420-442. doi: 10.1016/j.hlc.2023.11.027 |
|
2024 Journal Article Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?Ranjit Anderson, Nirija, Korczyk, Dariusz and Mollee, Peter (2024). Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?. Expert Review of Hematology, 17 (9), 567-579. doi: 10.1080/17474086.2024.2388184 |
|
2023 Journal Article Screening for and diagnosis of monoclonal gammopathyChong, Yuh Ping, Lim, Say Min, Loh, Tze Ping, Mollee, Peter, Wijeratne, Nilika and Choy, Kay Weng (2023). Screening for and diagnosis of monoclonal gammopathy. Journal of Clinical Pathology, 76 (11), 727-733. doi: 10.1136/jcp-2023-208774 |
|
2023 Journal Article Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaCass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007 |
|
2023 Journal Article Safety, feasibility, and acceptability of a multi-site individualized exercise intervention for people with multiple myelomaNicol, Jennifer L., Cunningham, Brent, Woodrow, Carmel, Adlard, Kirsten, Papinczak, Zoe, Spence, Rosalind R., Boytar, Alex N., Mollee, Peter, Weber, Nicholas, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2023). Safety, feasibility, and acceptability of a multi-site individualized exercise intervention for people with multiple myeloma. Medicine and Science in Sports and Exercise, 55 (12), 2214-2227. doi: 10.1249/mss.0000000000003267 |
|
2023 Journal Article Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myelomaTeh, Benjamin W., Reynolds, Gemma, Slavin, Monica A., Cooley, Louise, Roberts, Matthew, Liu, Eunice, Thursky, Karin, Talaulikar, Dipti, Mollee, Peter, Szabo, Ferenc, Ward, Chris, Chan, Henry, Prince, H. Miles, Harrison, Simon J. and the Medical and Scientific Advisory Group, Myeloma Australia and National Centrefor Infections in Cancer (2023). Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma. Internal Medicine Journal, 53 (8), 1469-1477. doi: 10.1111/imj.16100 |
|
2023 Journal Article Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiographyFerkh, Aaisha, Tjahjadi, Catherina, Stefani, Luke, Geenty, Paul, Byth, Karen, De Silva, Kasun, Boyd, Anita C., Richards, David, Mollee, Peter, Korczyk, Dariusz, Taylor, Mark S., Kwok, Fiona, Kizana, Eddy, Ng, Arnold C. T. and Thomas, Liza (2023). Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography. Frontiers in Cardiovascular Medicine, 10 1183485. doi: 10.3389/fcvm.2023.1183485 |
|
2023 Journal Article The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma AustraliaSim, Shirlene, Kalff, Anna, Tuch, Gina, Mollee, Peter, Ho, Joy, Harrison, Simon, Gibbs, Simon, Prince, H. Miles, Spencer, Andrew, Joshua, Douglas, Lee, Cindy, Ling, Silvia, Murphy, Nick, Szabo, Ferenc, Szer, Jeff, Weber, Nicholas, Ward, Christopher, Talaulikar, Dipti, Zannettino, Andrew and Quach, Hang (2023). The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma Australia. Internal Medicine Journal, 53 (5), 819-824. doi: 10.1111/imj.16049 |
|
2023 Journal Article Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemiaBurgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631 |
|
2023 Journal Article Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic reviewNicol, Jennifer L., Chong, Jamie E., McQuilten, Zoe K., Mollee, Peter, Hill, Michelle M. and Skinner, Tina L. (2023). Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia, 23 (2), 86-96. doi: 10.1016/j.clml.2022.10.003 |
|
2023 Journal Article Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphomaMistry, Vijay, Scott, Justin R., Wang, Tzu-Yang, Mollee, Peter, Miles, Kenneth A., Law, W. Phillip and Hapgood, Greg (2023). Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma. Cancer Imaging, 23 (1) 11, 1-11. doi: 10.1186/s40644-023-00520-7 |
|
2023 Journal Article The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand PopulationTan, Joanne L. C., Wellard, Cameron, Moore, Elizabeth M., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Harrison, Simon James, McDonald, Emma‐Jane, Ho, P. Joy, Prince, H. Miles, Augustson, Bradley M., Campbell, Philip, McQuilten, Zoe K., Wood, Erica M., Spencer, Andrew and Myeloma and Related Diseases Registry Investigators (2023). The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. British Journal of Haematology, 200 (2), e17-e21. doi: 10.1111/bjh.18536 |
|
2022 Journal Article Current approaches to the diagnosis and management of amyloidosisTaylor, Mark S., Sidiqi, Hasib, Hare, James, Kwok, Fiona, Choi, Bo, Lee, Darren, Baumwol, Jay, Carroll, Antonia S., Vucic, Steve, Neely, Pat, Korczyk, Dariusz, Thomas, Liza, Mollee, Peter, Stewart, Graeme J. and Gibbs, Simon D. J. (2022). Current approaches to the diagnosis and management of amyloidosis. Internal Medicine Journal, 52 (12), 2046-2067. doi: 10.1111/imj.15974 |
|
2022 Journal Article Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyLandgren, Ola, Weisel, Katja, Rosinol, Laura, Touzeau, Cyrille, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Shu, Natalie, Hu, Xuguang, Li, Chuang and Usmani, Saad Z. (2022). Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. British Journal of Haematology, 198 (6), 988-993. doi: 10.1111/bjh.18233 |
|
2022 Journal Article Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)McQuilten, Zoe, Wellard, Cameron, Moore, Elizabeth, Augustson, Bradley, Bergin, Krystal, Blacklock, Hilary, Harrison, Simon, Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rosengarten, Brian, Walker, Patricia, Wood, Erica, Spencer, Andrew and Australian and New Zealand Myeloma and Related Diseases Registry (2022). Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). British Journal of Haematology, 198 (5), 830-837. doi: 10.1111/bjh.18324 |
